In rheumatic heart disease-associated AF, rivaroxaban increased adverse vascular outcomes vs. VKA at 3 y

Ellis W Lader

doi:10.7326/J22-0102

In rheumatic heart disease-associated AF, rivaroxaban increased adverse vascular outcomes vs. VKA at 3 y

Ann Intern Med. 2023 Jan;176(1):JC2. doi: 10.7326/J22-0102. Epub 2023 Jan 3.

Author

Ellis W Lader¹

Affiliation

¹ WMCHealth Heart and Vascular Institute, Kingston, New York, United States (E.W.L.).

PMID: 36592467
DOI: 10.7326/J22-0102

Abstract

Connolly SJ, Karthikeyan G, Ntsekhe M, et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med. 2022;387:978-88. 36036525.

Publication types

Comment

MeSH terms

Anticoagulants / adverse effects
Atrial Fibrillation* / complications
Atrial Fibrillation* / drug therapy
Factor Xa Inhibitors / adverse effects
Humans
Rheumatic Heart Disease* / chemically induced
Rheumatic Heart Disease* / complications
Rivaroxaban / adverse effects
Stroke* / chemically induced
Stroke* / prevention & control
Treatment Outcome
Vitamin K

Substances

Rivaroxaban
Anticoagulants
Factor Xa Inhibitors
Vitamin K